NPS Buys Back Rights to Gattex From Takeda to Spur Sales
This article is for subscribers only.
NPS Pharmaceuticals Inc., a maker of rare-disease drugs, rose the most in five months after the company regained worldwide marketing and development rights to its therapy Gattex from partner Takeda Pharmaceutical Co.
NPS gained 9.3 percent to $9.88 at the close in New York, its largest single-day increase since Oct. 12. The company’s shares have increased 47 percent in the past 12 months.